Dr Fraser is the Chief Scientfic Officer of Angiocrine Biosciences Inc, a San Diego-based biotechnology company engaged in develoment of genetically engineered human endothelial cell products. He has more than 30 years of experience working with regenerative medicine in both academia and industry. Prior to joining Angiocrine, Dr Fraser had a 18 year career with Cytori Therapeutics developing adipose-derived regenerative cell therapy products. He was previously an Associate Professor in the Division of Hematology-Oncology and a member of the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles. For three years Dr Fraser was the Co-Director of the UCLA Bone Marrow Transplant Laboratory, the facility responsible for processing and cryopreservation of all bone marrow and peripheral blood stem cells used in marrow transplants at UCLA. In addition, Dr Fraser was a member of one of UCLA’s two Medical Institutional Review Boards for seven years and served as Vice Chair of one of the Board for two years. He has served on five NIH panels reviewing stem cell-related research proposals. Dr Fraser has a PhD from the University of Otago in New Zealand and a Bachelor of Science degree (Biochemistry and Physiology) from Victoria University of Wellington.